Ethicolegal aspects of cancer genetics.

Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Cancer treatment and research 01/2010; 155:1-14. DOI: 10.1007/978-1-4419-6033-7_1
Source: PubMed

ABSTRACT In the wake of efficacious preventive interventions based on hereditary cancer risk assessment, a number of ethical and legal challenges have emerged. These include issues such as appropriate testing of children and embryos, the "duty to warn" relatives about familial risk, reproductive genetic testing, the risk of genetic discrimination, and equitable access to testing. These and other issues will be discussed within the framework of a bioethical model, with reference to recent case law.

  • Current Problems in Cancer 10/2014; 38(6). DOI:10.1016/j.currproblcancer.2014.10.002 · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis of Lynch syndrome can lead to the prevention of colorectal cancer through periodic colonoscopies and removal of premalignant lesions in susceptible individuals. Therefore, predisposed individuals identified by mutation analysis are advised to inform their at-risk relatives about the options of predictive DNA testing and preventive measures. However, it has now been established that more than half of these relatives do not receive the necessary information. Barriers in conveying information include family communication problems and variable attitudes and practice among clinical geneticists. In this complex field, both medical, psychological, ethical and juridical aspects deserve consideration. Here we summarize the development of a revised guideline for clinical geneticists that allows a more active role of the geneticist, aimed at improving procedures to inform family members in Lynch syndrome and other hereditary and familial cancer syndromes.
    Familial Cancer 03/2013; DOI:10.1007/s10689-013-9636-9 · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The latest health care legislation, which promotes prevention and health screening, ultimately depends for its success on recognition of people's values concerning the technologies being employed, not just the interventions' technical virtues. Values concerning the deterministic nature of a condition and what groups should be targeted rest on a sense of what is morally, often religiously right in a given health circumstance. This paper looks at a number of leading-edge case examples-breast cancer genetic screening and family decision-making, and newborn screening and biobanks-in examining how the choices made at the individual, family, and societal levels rest on faith in a higher source of efficacy and moral perspectives on the measures that can be taken. Qualitative responses expressing people's attitudes toward these technologies underscore the importance of considering faith-based values in individual decisions and collective policies on their use. These examples are considered in the context of the historic interplay between science and religion and recent definitions and models of health which incorporate physical, emotional, and social elements, and most importantly, are expanding to incorporate the religious and spiritual values domains.
    Journal of Religion and Health 02/2014; 53(3). DOI:10.1007/s10943-013-9814-y · 1.02 Impact Factor


Available from